Literature DB >> 782976

Efficacy of a live oral typhoid vaccine in human volunteers.

R B Hornick, H L DuPont, M M Levine, R H Gilman, W E Woodward, M J Snyder, T E Woodward.   

Abstract

A live oral attenuated vaccine, lacking the enzyme epimerase, has been given with complete safety to 173 men. Two preparations of the vaccine, one with and one without galactose in the initial culture media, led to somewhat differing results. Vaccine A, prepared with galactose, was more readily identified in the stool specimens of its recipients and was more likely to provoke an O antibody response than was vaccine B. Furthermore, the clinical protection from typhoid fever was significant in the vaccine A group, whereas not so with the vaccine B counterpart. The protection afforded by vaccine A exceeds that of any of our previous candidate strains. It is perhaps not presumptuous to imagine that such a vaccine would be equally effective in an area endemic for typhoid fever, where the vaccine might act as a booster effect in a previously exposed population. Remaining questions to be answered include the duration of the protection, and the efficacy of a lyophilized preparation.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 782976

Source DB:  PubMed          Journal:  Dev Biol Stand        ISSN: 0301-5149


  3 in total

1.  Effective treatment and prevention of typhoid fever: updated.

Authors:  S L Hoffman; T E Woodward; R B Hornick; N H Punjabi; S E Greisman
Journal:  Trans Am Clin Climatol Assoc       Date:  1984

2.  Generating the Evidence for Typhoid Vaccine Introduction: Considerations for Global Disease Burden Estimates and Vaccine Testing Through Human Challenge.

Authors:  James E Meiring; Alberto Giubilini; Julian Savulescu; Virginia E Pitzer; Andrew J Pollard
Journal:  Clin Infect Dis       Date:  2019-10-15       Impact factor: 9.079

3.  Correlation of T cell response and bacterial clearance in human volunteers challenged with Helicobacter pylori revealed by randomised controlled vaccination with Ty21a-based Salmonella vaccines.

Authors:  T Aebischer; D Bumann; H J Epple; W Metzger; T Schneider; G Cherepnev; A K Walduck; D Kunkel; V Moos; C Loddenkemper; I Jiadze; M Panasyuk; M Stolte; D Y Graham; M Zeitz; T F Meyer
Journal:  Gut       Date:  2008-04-16       Impact factor: 23.059

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.